サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

黒色腫(メラノーマ)診断検査 − 医療機器パイプライン評価(2016年)

レポート概要

本レポートは、現在パイプライン段階に存在する黒色腫(メラノーマ)診断検査の概要を提供します。

また、開発のさまざまな段階にある製品を比較分析して、パイプライン製品に関する包括的な情報を提供し、パイプライン製品の開発に関与している主要企業を概説します。さらに、治験の段階、治験の状況、治験の開始・終了日、および重要な黒色腫(メラノーマ)診断検査パイプライン製品に対する治験件数を含む、進行中の治験に関する情報も提供します。

本レポートは、業界の専門家からなる自社チームによる独自のデータベース、一次調査と二次調査、および自社分析を基にしたデータや情報を盛り込んでいます。

■ 調査範囲

  • 開発中の黒色腫(メラノーマ)診断検査を概説します。
  • 製品概要、ライセンシングおよび共同開発、その他の開発活動など、主要なパイプライン製品に関する情報を提供します。
  • 黒色腫(メラノーマ)診断検査の開発に関与している主要企業の情報を提供し、それらの企業の全パイプラインプロジェクトをリストアップします。
  • 初期段階から承認/発売段階まで開発のさまざまな段階に基づくパイプライン製品を概説します。
  • パイプライン製品に特化した進行中の治験の重要な治験データを提供します
  • セグメント/業界における最近の開発を紹介します。

レポート詳細

目次

Table of Contents

1. Table of Contents
1.1. List of Tables
1.2. List of Figures

2. Introduction
2.1. Melanoma Diagnostic Tests Overview

3. Products under Development
3.1. Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
3.2. Melanoma Diagnostic Tests - Pipeline Products by Territory
3.3. Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
3.4. Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
3.5. Melanoma Diagnostic Tests - Ongoing Clinical Trials

4. Melanoma Diagnostic Tests - Pipeline Products under Development by Companies
4.1. Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2. Melanoma Diagnostic Tests - Pipeline Products by Stage of Development

5. Melanoma Diagnostic Tests Companies and Product Overview
5.1. Abbott Diagnostics Company Overview
5.1.1. Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.2. Adaptive Biotechnologies Corporation Company Overview
5.2.1. Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.3. Agilent Technologies, Inc. Company Overview
5.3.1. Agilent Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.4. BioMark Diagnostics Inc. Company Overview
5.4.1. BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.5. BioMarker Strategies, LLC Company Overview
5.5.1. BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.6. Biosceptre (Aust) Pty Ltd Company Overview
5.6.1. Biosceptre (Aust) Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.7. Bio-Techne Corp Company Overview
5.7.1. Bio-Techne Corp Pipeline Products & Ongoing Clinical Trials Overview
5.8. Boston University Company Overview
5.8.1. Boston University Pipeline Products & Ongoing Clinical Trials Overview
5.9. Ceres Nanosciences, Inc. Company Overview
5.9.1. Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.10. Dana-Farber Cancer Institute, Inc. Company Overview
5.10.1. Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.11. Digna Biotech, S.L. Company Overview
5.11.1. Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
5.12. Exosomics Siena SpA Company Overview
5.12.1. Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
5.13. Genentech, Inc. Company Overview
5.13.1. Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.14. Genomic Health, Inc. Company Overview
5.14.1. Genomic Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.15. Hospital Universitario Cruces Company Overview
5.15.1. Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
5.16. Hummingbird Diagnostics GmbH Company Overview
5.16.1. Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.17. ImmunID Company Overview
5.17.1. ImmunID Pipeline Products & Ongoing Clinical Trials Overview
5.18. Institut Pasteur Company Overview
5.18.1. Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview
5.19. InterGenetics Incorporated Company Overview
5.19.1. InterGenetics Incorporated Pipeline Products & Ongoing Clinical Trials Overview
5.20. IV Diagnostics, Inc. Company Overview
5.20.1. IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.21. John Hopkins University Company Overview
5.21.1. John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
5.22. Louisville Bioscience, Inc. Company Overview
5.22.1. Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.23. MDNA Life Sciences, Inc. Company Overview
5.23.1. MDNA Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.24. Melanovus Oncology, Inc. Company Overview
5.24.1. Melanovus Oncology, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.25. Memorial Sloan Kettering Cancer Center Company Overview
5.25.1. Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
5.26. MyCardio,LLC. Company Overview
5.26.1. MyCardio,LLC. Pipeline Products & Ongoing Clinical Trials Overview
5.27. Myriad Genetics, Inc. Company Overview
5.27.1. Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.28. Orion Genomics LLC Company Overview
5.28.1. Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.29. Oryzon Genomics SA Company Overview
5.29.1. Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
5.30. Pacific Edge Limited Company Overview
5.30.1. Pacific Edge Limited Pipeline Products & Ongoing Clinical Trials Overview
5.31. Protea Biosciences Group, Inc. Company Overview
5.31.1. Protea Biosciences Group, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.32. Qiagen N.V. Company Overview
5.32.1. Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview
5.33. Roche Diagnostics International Ltd. Company Overview
5.33.1. Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.34. Rosetta Genomics Ltd Company Overview
5.34.1. Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.35. Sividon Diagnostics GmbH Company Overview
5.35.1. Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.36. SomaLogic, Inc. Company Overview
5.36.1. SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.37. University of California, San Francisco Company Overview
5.37.1. University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview
5.38. University of Colorado Company Overview
5.38.1. University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
5.39. University of Louisville Company Overview
5.39.1. University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
5.40. University of Maryland, Baltimore Company Overview
5.40.1. University of Maryland, Baltimore Pipeline Products & Ongoing Clinical Trials Overview
5.41. Vanderbilt University Company Overview
5.41.1. Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
5.42. Zymera, Inc Company Overview
5.42.1. Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview

6. Melanoma Diagnostic Tests - Recent Developments
6.1. Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare
6.2. Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
6.3. Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results
6.4. Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline
6.5. Sep 15, 2016: Agilent Technologies Raises USD300 Million in Public Offering of Notes Due 2026
6.6. Sep 01, 2016: Novel Test Distinguishes Atypical Moles From Melanoma
6.7. Aug 31, 2016: bioMerieux - First-Half 2016 Results
6.8. Aug 29, 2016: Dr. Ann Hanham Joins HTG Molecular Diagnostics' Board of Directors
6.9. Aug 17, 2016: Agilent Technologies Reports Third-Quarter 2016 Results
6.10. Aug 16, 2016: Protea Announces Second Quarter 2016 Results
6.11. Aug 09, 2016: Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results
6.12. Aug 09, 2016: HTG Molecular Diagnostics Reports Second Quarter 2016 Results
6.13. Aug 08, 2016: Oryzon Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2016
6.14. Aug 02, 2016: Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance
6.15. Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
6.16. Jul 27, 2016: GSK announces significant new investment in UK manufacturing network
6.17. Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
6.18. Jul 21, 2016: Quest Diagnostics Reports Second Quarter 2016 Financial Results
6.19. Jul 18, 2016: bioMerieux - Second-Quarter 2016 Business Review
6.20. Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 Million award
6.21. Jul 06, 2016: Bio-Techne Acquires Advanced Cell Diagnostics
6.22. Jul 05, 2016: MolecularMD Raises USD0.5 Million in Venture Financing
6.23. Jul 04, 2016: Exiqon - Nomination of candidates for the supervisory board
6.24. Jun 23, 2016: HTG Molecular Diagnostics Announces VERI/O Laboratory Service
6.25. Jun 20, 2016: HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform
6.26. Jun 15, 2016: Quest Diagnostics and Safeway Team to Offer Convenient Diagnostic Testing to Customers in More States
6.27. Jun 14, 2016: GlaxoSmithKline: Executive Director Change
6.28. Jun 02, 2016: Pacific Edge Board Changes Announced
6.29. May 31, 2016: Myriad Genetics Acquires Sividon Diagnostics
6.30. May 31, 2016: Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals
6.31. May 27, 2016: Protea Biosciences to Raise Funds through Public Offering of Shares
6.32. May 23, 2016: Quest Diagnostics Raises USD500 Million in Public Offering of 3.45% Senior Notes due 2026
6.33. May 20, 2016: International Comparison of BRAF Testing in Melanoma Abstract Released in Conjunction With ASCO 2016
6.34. May 20, 2016: Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company
6.35. May 16, 2016: Agilent Technologies Reports Second-Quarter 2016 Results
6.36. May 16, 2016: Protea Announces First Quarter 2016 Results
6.37. May 12, 2016: Oryzon Reports First Quarter 2016 Financial Results and Corporate Update
6.38. May 12, 2016: HTG Molecular Diagnostics Reports First Quarter 2016 Results
6.39. May 11, 2016: Dako, an Agilent Technologies Company, Announces Expanded Use of PD-L1 Diagnostic Test in Europe
6.40. Apr 25, 2016: Protea Biosciences Enters into Licensing Agreement with Yale University
6.41. Mar 31, 2016: ImmunTraCkeR Results on Prediction of Response to Cancer Immunotherapy Selected for Presentation at ASCO Annual Meeting
6.42. Mar 15, 2016: Myriad Presents Second Pivotal Validation Study for Its myPath Melanoma Test
6.43. Feb 23, 2016: ImmunID Signs Master Collaboration Agreement with MSK about the Prediction of Response to Immuno-Oncology Agents Using ImmunTraCkeR
6.44. Feb 15, 2016: Collaboration led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy using ImmunTraCkeR
6.45. Jan 25, 2016: Quest Diagnostics Expands Dako's PD-L1 IHC 28-8 Complementary Test to Include Melanoma
6.46. Jan 25, 2016: Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma
6.47. Jan 11, 2016: Blood Test that Monitors Dead Cancer Cell DNA Better at Tracking Spread of Melanoma

7. Appendix
7.1. Methodology
7.2. About GlobalData
7.3. Contact Us
7.4. Disclaimer

List of Tables
Table 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Melanoma Diagnostic Tests - Pipeline Products by Territory
Table 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials
Table 6: Melanoma Companies - Pipeline Products by Stage of Development
Table 7: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 9: MAGE-A3 Companion Skin Cancer Assay - Product Status
Table 10: MAGE-A3 Companion Skin Cancer Assay - Product Description
Table 11: Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Companion Diagnostic Test - Melanoma Cancer - Product Status
Table 13: Companion Diagnostic Test - Melanoma Cancer - Product Description
Table 14: Agilent Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 15: MK-3475 Companion Diagnostic Test - Product Status
Table 16: MK-3475 Companion Diagnostic Test - Product Description
Table 17: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Metabolomics-Based Diagnostic Assay - Melanoma - Product Status
Table 19: Metabolomics-Based Diagnostic Assay - Melanoma - Product Description
Table 20: BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Ex Vivo Biomarker Test - Melanoma - Product Status
Table 22: Ex Vivo Biomarker Test - Melanoma - Product Description
Table 23: PathMAP - Product Status
Table 24: PathMAP - Product Description
Table 25: Biosceptre (Aust) Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Skin Cancer IHC Diagnostic Test - Product Status
Table 27: Skin Cancer IHC Diagnostic Test - Product Description
Table 28: Bio-Techne Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 29: RNAscope MELA - Product Status
Table 30: RNAscope MELA - Product Description
Table 31: Boston University Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Microfluidic Chip - Melanoma - Product Status
Table 33: Microfluidic Chip - Melanoma - Product Description
Table 34: Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Melanoma Skin Patch Sweat Test - Product Status
Table 36: Melanoma Skin Patch Sweat Test - Product Description
Table 37: Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Status
Table 39: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Description
Table 40: Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Melanoma Test - Product Status
Table 42: Melanoma Test - Product Description
Table 43: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
Table 44: EXOTEST Melanoma - Product Status
Table 45: EXOTEST Melanoma - Product Description
Table 46: Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 47: Cobimetinib Companion Diagnostic Assay - Product Status
Table 48: Cobimetinib Companion Diagnostic Assay - Product Description
Table 49: Genomic Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Prognostic Test - Melanoma - Product Status
Table 51: Prognostic Test - Melanoma - Product Description
Table 52: Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
Table 53: Diagnostic Assay - Melanoma - Product Status
Table 54: Diagnostic Assay - Melanoma - Product Description
Table 55: Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 56: Diagnostic Test - Melanoma - Product Status
Table 57: Diagnostic Test - Melanoma - Product Description
Table 58: ImmunID Pipeline Products & Ongoing Clinical Trials Overview
Table 59: ImmunTraCkeR - Metastatic Melanoma - Product Status
Table 60: ImmunTraCkeR - Metastatic Melanoma - Product Description
Table 61: ImmunID - Ongoing Clinical Trials Overview
Table 62: ImmunTraCkeR - Metastatic Melanoma - Multicenter Clinical Study to Assess the Use of Immune Competence Profiles evaluated by ImmunTracker in Metastatic Melanoma Subjects Treated with an Immune Checkpoint Inhibitor
Table 63: ImmunTraCkeR - Metastatic Melanoma - Validation of ImmunTraCkeR in Metastatic Melanoma Patients - A Medico-economic Clinical Study
Table 64: Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Diagnostic Test - Melanoma - Product Status
Table 66: Diagnostic Test - Melanoma - Product Description
Table 67: InterGenetics Incorporated Pipeline Products & Ongoing Clinical Trials Overview
Table 68: OncoVue Skin - Product Status
Table 69: OncoVue Skin - Product Description
Table 70: IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 71: IVDiagnostics Diagnostic Test - Melanoma - Product Status
Table 72: IVDiagnostics Diagnostic Test - Melanoma - Product Description
Table 73: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
Table 74: Biomarker Based Diagnostic Assay - Melanoma - Product Status
Table 75: Biomarker Based Diagnostic Assay - Melanoma - Product Description
Table 76: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Melanoma Remission pT Test - Product Status
Table 78: Melanoma Remission pT Test - Product Description
Table 79: MDNA Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Diagnostic Test - Melanoma - Product Status
Table 81: Diagnostic Test - Melanoma - Product Description
Table 82: Melanovus Oncology, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 83: Companion Diagnostic Test - Melanoma - Product Status
Table 84: Companion Diagnostic Test - Melanoma - Product Description
Table 85: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
Table 86: Melanoma Biomarker - Resistance to RAF Inhibitors - Product Status
Table 87: Melanoma Biomarker - Resistance to RAF Inhibitors - Product Description
Table 88: MyCardio,LLC. Pipeline Products & Ongoing Clinical Trials Overview
Table 89: Diagnostic Assay - Melanoma - Product Status
Table 90: Diagnostic Assay - Melanoma - Product Description
Table 91: Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 92: myPath Melanoma - Product Status
Table 93: myPath Melanoma - Product Description
Table 94: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 95: Diagnostic Assay - Melanoma - Product Status
Table 96: Diagnostic Assay - Melanoma - Product Description
Table 97: Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
Table 98: Diagnostic Assay - Melanoma Cancer - Product Status
Table 99: Diagnostic Assay - Melanoma Cancer - Product Description
Table 100: Prognostic Assay - Melanoma Cancer - Product Status
Table 101: Prognostic Assay - Melanoma Cancer - Product Description
Table 102: Pacific Edge Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 103: Prognostic Assay - Melanoma - Product Status
Table 104: Prognostic Assay - Melanoma - Product Description
Table 105: Protea Biosciences Group, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 106: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Status
Table 107: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Description
Table 108: Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview
Table 109: Companion Diagnostic Test - Binimetinib - Product Status
Table 110: Companion Diagnostic Test - Binimetinib - Product Description
Table 111: NRAS Assay-Melanoma - Product Status
Table 112: NRAS Assay-Melanoma - Product Description
Table 113: Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 114: Companion Diagnostic Test - MEK 0973 - Product Status
Table 115: Companion Diagnostic Test - MEK 0973 - Product Description
Table 116: ETBR ADC Companion Diagnostic Test - Product Status
Table 117: ETBR ADC Companion Diagnostic Test - Product Description
Table 118: PDL1+Zelboraf Companion Diagnostic Test - Product Status
Table 119: PDL1+Zelboraf Companion Diagnostic Test - Product Description
Table 120: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Status
Table 121: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Description
Table 122: Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 123: microRNA-Based Diagnostic Test - Melanoma - Product Status
Table 124: microRNA-Based Diagnostic Test - Melanoma - Product Description
Table 125: Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 126: Diagnostic Assay - Melanoma - Product Status
Table 127: Diagnostic Assay - Melanoma - Product Description
Table 128: SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 129: SOMAscan Assay - Melanoma - Product Status
Table 130: SOMAscan Assay - Melanoma - Product Description
Table 131: University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview
Table 132: Diagnostic Assay - Uveal Melanoma - Product Status
Table 133: Diagnostic Assay - Uveal Melanoma - Product Description
Table 134: University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
Table 135: Diagnostic Test - Metastatic Melanoma - Product Status
Table 136: Diagnostic Test - Metastatic Melanoma - Product Description
Table 137: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
Table 138: Melanoma Sentinel Lymph Node Biomarker Test - Product Status
Table 139: Melanoma Sentinel Lymph Node Biomarker Test - Product Description
Table 140: University of Maryland, Baltimore Pipeline Products & Ongoing Clinical Trials Overview
Table 141: Prognostic Biomarker Test - Melanoma - Product Status
Table 142: Prognostic Biomarker Test - Melanoma - Product Description
Table 143: Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
Table 144: Companion Diagnostic Assay - Melanoma - Product Status
Table 145: Companion Diagnostic Assay - Melanoma - Product Description
Table 146: Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 147: Prognostic Assay - Melanoma - Product Status
Table 148: Prognostic Assay - Melanoma - Product Description
Table 149: Glossary

List of Figures
Figure 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Melanoma Diagnostic Tests - Pipeline Products by Territory
Figure 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
Figure 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
Figure 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials

発刊日

2016/11/01

体裁

PDF / 134ページ

販売価格

4,000USD

発行

GlobalData

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

診断・検査薬 / 企業 / 医療器具・機器

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE